News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Resolv ER may remedy leading causes of blindness in adults
Subscribe To Our Newsletter & Stay Updated
